This Article Full Text Full Text (PDF) All Versions of this Article: 136/6/691    most recent REP-08-0096v1 Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Meistrich, M. L Articles by Shetty, G. Search for Related Content PubMed PubMed Citation Articles by Meistrich, M. L Articles by Shetty, G.

Hormonal suppression for fertility preservation in males and females

Department of Experimental Radiation Oncology, MD Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Houston, Texas 77030, USA

Correspondence should be addressed to G Shetty; Email: sgunapal{at}mdanderson.org

Methods to restore fertility of men and women sterilized by medical treatments and environmental toxicant exposures are under investigation. Rendering spermatogenesis and ovarian follicular development kinetically quiescent by suppression of gonadotropins has been proposed to protect them from damage by cytotoxic therapy. Although the method fails to protect the fertility of male mice and monkeys, gonadotropin and testosterone suppression in rats before or after cytotoxic therapy do enhance the recovery of spermatogenesis. However, the mechanism involves not the induction of quiescence but rather the reversal, by suppression of testosterone, of a block in differentiation of surviving spermatogonia caused by damage to the somatic environment. In men, only one of eight clinical trials was successful in protecting or restoring spermatogenesis after cytotoxic therapy. In women, protection of primordial follicles in several species from damage by cytotoxic agents using GnRH analogs has been claimed; however, only two studies in mice appear convincing. The protection cannot involve the induction of quiescence in the already dormant primordial follicle but may involve direct effects of GnRH analogs or indirect effects of gonadotropin suppression on the whole ovary. Although numerous studies in female patients undergoing chemotherapy indicate that GnRH analogs might be protective of ovarian function, none of the studies showing protection were prospective randomized clinical trials and thus they are inconclusive. Considering interspecies differences and similarities in the gonadal sensitivity to cytotoxic agents and hormones, mechanistic studies are needed to identify the specific beneficial effects of hormonal suppression in select animal models that may be applicable to humans.

This article has been cited by other articles:

				J. S. Jeruss and T. K. Woodruff Preservation of Fertility in Patients with Cancer N. Engl. J. Med., February 26, 2009; 360(9): 902 - 911. [Full Text] [PDF]

				R A Anderson Fertility preservation techniques: laboratory and clinical progress and current issues Reproduction, December 1, 2008; 136(6): 667 - 669. [Abstract] [Full Text] [PDF]